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Background/aim: Cushing’s disease (CD), which cannot be controlled by surgery, requires medical treatment. In this situation,
treatments with long-term effectiveness and safety profiles are needed. We aimed to evaluate the effects and adverse effects of pasireotide
treatment in CD.
Materials and methods: Patients who were followed up for CD and treated with pasireotide between 2014–2020 at Cerrahpaşa Medical
Faculty, were evaluated retrospectively. The efficacy and adverse effects of pasireotide were evaluated in this study.
Results: Thirty-two patients were evaluated. The mean duration of treatment was 26.5 [range, 12.0–37.0] months. The 24-h urinary
free cortisol (UFC) decreased 46% during the treatment and normalized in 37.5% of patients. A significant decrement was found
between pretreatment and last follow-up UFC (p = 0.001). Plasma ACTH decreased by 21%. A significant decrement was found between
pre-treatment and the 3rd month, 6th month, and last follow-up ACTH levels (p = 0.014, p = 0.017, and p = 0.017, respectively).
Serum cortisol levels decreased by 18% and a significant decrement was found between pretreatment and the 3rd month, and between
pretreatment and the last follow-up (p = 0.034 and p = 0.013, respectively). While fasting blood glucose at the 3rd month was significantly
higher than pretreatment fasting blood glucose, no significant difference was found between pretreatment fasting blood glucose and 6th
month and last follow-up fasting blood glucose. Although there was a significant difference between pretreatment HbA1c levels and the
HbA1c levels at the 3rd month (5.9% vs. 6.6% p = 0.007), 6th month (5.9% vs. 6.7% p = 0.003), and the last follow-up (5.9% vs. 7.1% p
= 0.001), in the last follow-up, the majority (77%) of patients had adequate glycemic control (HbA1c ≤ 7.0 %).
Conclusion: Pasireotide treatment is an alternative treatment in CD, remission is obtained in the first months of treatment, and
continues for an extended period. Although hyperglycemia is the most common adverse effect, it can be successfully controlled.
Keywords: Cushing’s disease, pasireotide treatment, hyperglycemia, hypercortisolism, UFC

1. Introduction
Cushing’s disease (CD) is a rare endocrine disorder
associated with severe mortality and morbidity [1]. The
annual incidence of CD is between 1.2 and 2.4 cases per
million [2–4]. The most common clinical features of CD
include obesity, diabetes, hypertension, moon facies, and
facial plethora [5,6]. Diabetes, cardiovascular events,
immunosuppression, osteoporosis, and psychiatric
disturbances are associated with morbidity in patients with
CD [7]. The estimated standard mortality rate for untreated
patients with CD is 1.9%–4.8% [8–10]. Although mortality
of patients with hypercortisolism in remission is lower
than that of patients with persistent hypercortisolism, it
is still high in these patients compared with the general
population [11,12].
The primary treatment for CD is pituitary surgery.
However, the remission rate ranges from 25% to 100%

with expert pituitary surgeons, and the relapse rate is
around 50% [13–17]. Resurgery, radiotherapy, bilateral
adrenalectomy, and medical treatment are among the
treatment options for patients with uncontrolled or
relapsed CD [18]. Resurgery may not be appropriate in
some patients because of high surgical risk, unresectable
tumor, high hypopituitarism risk, and lower remission
rates [19,20]. The other treatment option is radiotherapy,
but its therapeutic effect is delayed and there are important
central nervous system adverse effects [21]. Bilateral
adrenalectomy requires lifetime use of glucocorticoid and
mineralocorticoid therapy and carries the risk of Nelson
syndrome [17].
Among the medical treatment options are
ketoconazole, mitotane, metyrapone, mifepristone,
dopamine agonists, and somatostatin receptor ligands
(SRL) [1,18]. When evaluated in terms of their mechanism
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of action, there are dopamine agonists and SRLs among
drugs that act on corticotroph cells. SRLs with high affinity
for somatostatin receptors (SSTRs)-2, such as octreotide
and lanreotide, are used effectively in the treatment of
acromegaly and gastroenteropancreatic neuroendocrine
tumors, but they have been unsuccessful in their use in
CD due to their medium and low affinity for the remaining
SSTRs subtypes [22, 23]. In vitro studies, strong SSTR-5
expression was shown in corticotropic tumor cells in CD.
SSTR-5 expression is unaffected by hypercortisolemia,
while SSTR-2 expression is suppressed but can upregulate
with eucortisolemia [24,25]. Pasireotide binds with
high affinity to SSTR-1, SSTR-2, SSTR-3, SSTR-5, and
also binds to SSTR-5 with 40-fold higher affinity than
octreotide [24,25]. SSTR-5 expression in corticotropic
tumor cells and high affinity of pasireotide may explain
the potential effect of pasireotide on CD. In this study, we
aimed to evaluate the long-term effects and adverse effects
of pasireotide treatment.
2. Materials and methods
2.1. Participants
Patients who were followed up in Cerrahpaşa Medical
Faculty and received pasireotide treatment between 2014–
2020 were evaluated. The patients’ data included in the
study were retrospectively collected from their medical
records. Patients who were aged over 18 years and received
pasireotide treatment were included. Patients who had a
risk of long QT syndrome, uncontrolled diabetes, liver
and kidney failure, and pregnant patients were excluded.
The patients were retrospectively evaluated pretreatment,
at the 1st, 3rd, and 6th months, and the 1st year of the
treatment, and 1-year intervals thereafter.
2.2. Clinical evaluation
Clinical parameter evaluation of each visit was
retrospectively recorded. The clinical parameters included
systemic arterial hypertension, weight, myopathy, and
plethora. Normalization of arterial hypertension, weight
reduction, and regression of myopathy was accepted as
clinical improvement. According to the guidelines of the
American Society of Hypertension and the International
Society of Hypertension, systolic blood pressure ≥ 140
mmHg and/or diastolic blood pressure ≥ 90 mmHg or
treatment of a previously diagnosed hypertension was
defined as systemic arterial hypertension [26]. The patients’
age, sex, total disease duration, preoperative adenoma size,
Crooke cell presence, Ki-67 labeling index, the number of
surgical procedures, and the presence of radiotherapy were
evaluated. The tumor size was evaluated using the largest
tumor diameter on magnetic resonance imaging (MRI).
2.3. Evaluation of pasireotide treatment
The effectiveness of pasireotide treatment was evaluated
using basal serum cortisol, plasma adrenocorticotropic
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hormone (ACTH) level, salivary cortisol, 24-h urinary
free cortisol (UFC), the upper limit of normal (ULN)
for UFC, duration and doses of pasireotide treatment,
the time between pituitary surgery, pituitary hormone
status after pituitary surgery, and initiation of pasireotide
and clinical parameters. Patients with UFC ≤ ULN and
clinical improvement were defined as controlled, patients
with a UFC ≥ ULN but with a decrease of more than
50% and clinical improvement were defined as partially
controlled, and the other patients as uncontrolled. Patients
who received radiotherapy before or during pasireotide
treatment or who underwent surgery during pasireotide
treatment were considered uncontrolled patients.
2.4. Safety analysis
Patients were evaluated based on their medical records in
terms of adverse effects that occurred due to pasireotide
treatment. Antidiabetic agents used in the treatment of
type 2 diabetes (T2DM), fasting blood glucose (FBG),
and glycated hemoglobin (HbA1c) values, hepatobiliary
ultrasonography findings, liver enzymes [alanine
aminotransferase (ALT), aspartate aminotransferase
(AST)], and electrocardiography (ECG) findings were
evaluated.
2.5. Assays
FBG and liver enzymes (ALT, AST) were analyzed
using Roche/Hitachi Cobas c systems according to
the manufacturer’s kits and recommendations (Roche
Diagnostics GmbH, Mannheim). The HbA1c levels were
measured using an International Federation of Clinical
Chemistry (IFCC)-certified automated high-performance
liquid chromatographic method (Lifotronic H9, M/s
SVR Biotech, Hyderabad, India). Salivary cortisol was
measured using an automated electrochemiluminescence
immunoassay (ECLIA) (Roche; Cobas e 601). Plasma
ACTH, serum cortisol, and UFC were assayed using an
ECLIA method with Roche Cobas e systems (Roche, Cobas
e 602, Roche Diagnostics GmbH, Mannheim, Germany).
2.6. Statistical analysis
The data were analyzed using the Statistical Package for the
Social Science program, SPSS 25.0 (SPSS, Inc, Chicago, IL,
USA). The findings of the study are presented as numbers
and percentages for categorical variables, and mean,
standard deviation, median, minimum, and maximum for
continuous variables. Comparisons between categorical
variables such as disease control rate (among groups
with mild, moderate, and severe disease severity), sex,
and disease severity (between control and uncontrolled
groups) were made using the chi-square (χ2) test. The
distribution of variables was examined using the ShapiroWilk test. We compared the parameters with normally
distribution pre and posttreatment with the pairedsamples t-test, and the parameters with nonnormally
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distribution with the Wilcoxon signed-ranks test. In
addition, between controlled and uncontrolled groups,
the parameters with normally distribution were evaluated
with an independent sample t-test, and the parameters
with nonnormally distribution with the Mann-Whitney
U test. In correlation analysis, Pearson’s correlation
coefficient was used in the case of normally distributed
data, and Spearman’s correlation coefficient was used with
nonnormally distributed data. Statistical significance was
set as p < 0.05 with a confidence level of 95%.
This study was approved by the local ethics committee
(approval number: 77992). The study adhered to the tenets
of the Declaration of Helsinki.
3. Results
3.1. Demographic data
The medical records of 201 patients with CD followed
in Cerrahpaşa Medical Faculty were retrospectively
reviewed. Thirty-four of 201 patients with CD were
receiving pasireotide treatment. Thirty-two of 34 patients
treated with pasireotide were evaluated. Two patients were
excluded because they did not attend regular follow-up.

Twenty-five (78%) of the patients were female, and seven
(22%) were male. The mean age at the time of diagnosis
was found as 39.75 ± 11.1 years. The median follow-up
period was 86.0 [range, 55.0–130.0] months. The general
features of the patients are shown in Table 1. The mean
duration of pasireotide treatment was 26.5 [range, 12.0–
37.0] months. The mean pasireotide initial dosage was
0.919 ± 0.37 mg/day, the initial dose of pasireotide was
0.6 mg/day in 17 patients, 1.2 mg/day in 13 patients, and
1.8 mg/day in two patients. The mean pasireotide dose at
the last follow-up was 1.088 ± 0.50 mg/day. The last dose
of pasireotide was 0.3 mg/day in two patients, 0.6 mg/
day in 11 patients, 1.2 mg/day in 11 patients, and 1.8 mg/
day in 8 patients. Postoperative data of 27 (84%) patients
are available. FSH and LH deficiency was detected in two
(7%) of these patients, and only LH (3%) deficiency was
detected in one patient. Postoperative diabetes insipidus
developed in one (3%) patient.
3.2. Effectiveness of pasireotide treatment
A decrease of 46% was found in the UFC values of
the patients after pasireotide treatment. There was no
significant difference between pretreatment UFC values

Table 1. General features of patients.
The laboratory parameters prepasireotide treatment
Serum cortisol (µg/dL) (n = 32) (mean ± sd)

18.1 ± 5.7

Plasma ACTH, (pg/mL) (n = 32) (mean ± sd)

48.1 ± 28.0

UFC, (mg/day) (n = 32) (mean ± sd)

189.7 ± 116.0

Salivary cortisol (µg/dL) (n = 11) (median [IQR])

0.34 [0.06–0.6]

The adenoma size in the initial pituitary MRI (n = 23) (mm) (mean ± sd)

7.1 ± 5.0

The adenoma in the initial pituitary MRI (n = 27)
Microadenoma (n (%))

17(53.0)

Macroadenoma (n (%))

6 (18.8)

Absence of adenoma (n (%))

4 (12.5)

The pathology features
The presence of Crooke cell (n (%))

11 (78.5)

Ki-67 % labelling index (n = 18) (median [IQR])

1.0 [1.0–3.0]

Surgery (number of operation)
1 operation (n (%))
2 operation (n (%))
3 operation (n (%))

18 (56)
12 (37)
2 (6)

Radiotherapy (n (%))

8(25)

ULN (≥ULN) (n = 32) (disease activity according to UFC)
Mild (≥ULN × 1-2) (n (%))
Moderate(≥ULN × 2.1–5) (n (%))
Severe (≥ULN × 5.1) (n (%))

11 (34)
14 (43)
7 (21)

ACTH: Adrenocorticotropic hormone, IQR: Interquartile range, UFC: Urinary free cortisol, ULN:
Upper limit of normal
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and those at the 1st (151.0 [105.8–251.2] vs. 120.7 [57.4–
264.4], p = 0.446), 3rd (151.0 [105.8–251.2] vs. 93.0
[51.3–220.5], p =0.114), and 6th (151.0 [105.8–251.2]
vs. 113.0 [42.0–160.8], p =0.078) months. However, the
last follow-up UFC was significantly lower compared
with the pretreatment UFC (151.0 [105.8–251.2] vs. 68.7
[24.6–142.5], p = 0.001). UFC values were normalized in
12 (37.5%) patients (controlled disease), and a decrease
of more than 70% was detected in the UFC of three (9%)
patients (partially controlled disease). The remission rates
at the 3rd month and last follow-ups are given in Figure 1.
Although there was no statistical significance, the rate of
disease control in severe disease was lower than in mild
and moderate disease UFC (UFC ≤ 5 × ULN) both at the
3rd month and at the last follow-up.
In the patients whose UFC normalized, ketoconazole
treatment was added instead of an increase in pasireotide
dose due to uncontrolled hyperglycemia in the treatment
of two patients. However, because of insufficient response,
ketoconazole treatment was discontinued, and the dose of
pasireotide treatment was increased, and hyperglycemia
was controlled with insulin and oral antidiabetic agents.
In 62.5% of the patients who were controlled in the 3rd
month, the control status continued at the last followups. In contrast, 41.6% of the patients who were not
controlled at 3 months were controlled at the last followups. According to the fit hypothesis analysis (Kappa
test), the treatment response at the third month could
not predict the response at the last follow-up (p = 0.274).
After pasireotide treatment, a 21% decrease in ACTH,
18% decrease in serum cortisol, and 48% decrease in

salivary cortisol values were found. In addition, there
was a significant decrease in UFC, ACTH, and cortisol
levels between pretreatment and the last follow-up, but no
significant difference was found in salivary cortisol values.
These parameters are shown in Table 2. An improvement
in myopathy in 14 (43%) patients, an improvement in
facial plethora in 3 (9%) patients, and a decrease in weight
in 16 (50%) patients were detected. A significant decrease
was found in patient weights between pretreatment and
the last follow-up (81.7 ± 17.7 vs. 75.7 ± 15.1 kg, p = 0.016),
and a mean difference in weights of 6 kg.
Twenty-four (75%) patients had a diagnosis of
systemic arterial hypertension prepasireotide treatment,
and eight (25%) patients did not. Twenty-one (87.5%)
of the 24 patients diagnosed as having systemic arterial
hypertension received medical treatment, three (12.5%)
did not receive medical treatment prepasireotide treatment.
At the last follow-ups, 18 (56%) patients were continuing
medical treatment due to hypertension, and 14 (44%)
patients had normal blood pressure without medication.
In addition, medical treatments due to hypertension
were discontinued in three (14%) of 21 patients after
pasireotide treatment. There was a significant difference
between the pretreatment and last follow-up systole and
diastolic blood pressures of the patients (p = 0.016 and p
= 0.026, respectively). The median systole/diastole blood
pressures were 127.5 [118.7–140.0]/80 [70.0–80.0] mmHg
pretreatment, and 120.0 [117.5–122.5]/70.0 [70.0–76.2]
mmHg at the last follow-up. Systolic and diastolic blood
pressure was <140/90mm Hg in all patients receiving
medical therapy at the last follow-ups.

Figure 1 The percentage of patients who disease was controlled at the 3rd
month and last control, and duration of pasireotide treatment
60.0
57.1

50.0
45.5

40.0

35.7

30.0

28.6
20.0
10.0
0.0

18.2

14

11
Mild Disease
3rd month (%)

14.3
7

Moderate Disease
Last control (%)

Severe Disease

Duration of treatment (month)

UFC: Urinary free cortisol, Mild disease: UFC ≥ ULN X 1-2,
Moderate disease: UFC ≥ ULN X 2.1-5, Severe disease: UFC ≥ ULN X 5.1

Figure 1. The percentage of patients whose disease was controlled at the 3rd month and last
control, and duration of pasireotide treatment.
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3.3. Predictive factors of pasireotide treatment response
The rate of controlled patients (total and partial controlled)
was 15/32 (46%). No significant difference was found
between controlled and uncontrolled patients in terms of
age, sex, disease severity, initial plasma ACTH, initial serum
cortisol, initial salivary cortisol, initial UFC levels, FBG
(initial and 3rd month), and HbA1c values (initial and 3rd
month). Furthermore, there was no significant difference in
terms of pathologic features (Ki-67 labeling index, mitosis,
presence of Crooke cells), adenoma size, weight change,
total pasireotide treatment time, initial and last pasireotide
treatment dose, the time between pituitary surgery and

initiation of pasireotide treatment, and median systolic/
diastolic blood pressures between the controlled and
uncontrolled patients. The general features of controlled
and uncontrolled patients are shown in Table 3
3.4. Adverse effects of pasireotide treatment
During the pasireotide treatment, gastrointestinal
symptoms developed in three (9%) patients, and the
drug was discontinued in one (3%) of these patients due
to severe adverse effects. There was no significant change
in the liver enzymes of the patients. Three (9%) patients
underwent cholecystectomy during pasireotide treatment,
two of whom had a history of cholelithiasis before the

Table 2. The comparison of pretreatment and 3rd month, 6th month, and last control of the laboratory parameters.

UFC levels (mg/day), median [IQR]

Pretreatment

3rd month

151.0 [105.8–251.2]

93.0 [51.3–220.5] 113.0 [42.0–160.8]

68.7 [24.6–142.5]

0.114

0.078

0.001

38.3 ± 19.7

35.0 ± 18.8

38.0 ± 23.0

0.014

0.017

0.017

15.2 ± 6.0

15.7 ± 5.7

14.8 ± 5.4

0.034

0.076

0.013

0.2 [0.1–0.4]

0.2 [0.07–0.4]

0.1 [0.1–0.3]

0.285

0.446

0.207

p
ACTH levels (pg/mL), mean ± sd

48.1 ± 28.0

p
Baseline cortisol levels (µg/dL), mean ± sd

18.1 ± 5.7

p
Salivary cortisol levels (µg/dL), median [IQR]

0.34 [0.06–0.6]

p

6th month

Last control

ACTH: Adrenocorticotropic hormone, UFC: Urinary free cortisol, IQR: Interquartile range.
Table 3. The comparison of demographic, clinical, and laboratory parameters of controlled and uncontrolled patients.
Controlled patients (n: 15)

Uncontrolled patients (n: 17)

p

Sex (F (%)/M (%))

10 (66.7) / 5 (33.3)

15 (88.2)/2 (11.8)

0.209

Age (years)

39.5 ±10.5

39.9 ± 11.9

0.920

Pretreatment baseline cortisol (µg/dL)

17.8 ± 5.3

18.4 ± 6.2

0.680

Pretreatment ACTH (pg/mL)

40.0 [21.1–59.0]

54.0 [25.2–71.7]

0.350

Pretreatment UFC mg/day

147.0 [107.0–230.0]

155.0 [105.2–287.8]

0.911

Pretreatment salivary cortisol µg/dL

0.29 [0.06–0.58]

0.43 [0.12–3.4]

0.556

Pretreatment FBG mg/dL

90.0 [82.0–96.5]

82.5 [78.0–119.0]

0.746

Pretreatment HbA1c (%)

6.0 [5.5–6.3]

5.8 [5.4–6.3]

0.605

The adenoma size in the initial pituitary MRI (mm)

5.0 [4.0–9.2]

5.0 [3.7–11.0]

0.879

The presence of Crooke cell (n, %))

5 (71.4)

6 (85.7)

1.000

Ki-67 % labelling index (median [IQR])

1.0 [0.7–5.7]

2.0 [1.0–3.0]

0.660

Total pasireotide treatment time (months)

36.0 [12.0–44.0]

24.0 [9.0–36.5]

0.105

Pasireotide initial dose mg/day

1.2 [0.6–1.2]

0.6 [0.6–1.2]

0.576

Weight pretreatment

82.5 [65.0–109.5]

79.2 [70.0–87.0]

0.667

F: Female, M: Male, ACTH: Adrenocorticotropic hormone, UFC: Urinary free cortisol, FBG: Fasting Blood Glucose
MRI: Magnetic resonance imaging, IQR: Interquartile range
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pasireotide treatment. During the pasireotide treatment,
received treatment for T2DM, the target HbA1c values
no serious QT prolongation was detected, but one patient
(≤7%) were reached at the last follow-up. At the last
with known coronary artery disease had acute myocardial
follow-up, 23 (71%) patients were using metformin, 18
infarction while taking pasireotide, and one patient was
(56%) used DPP-4 (dipeptidyl peptidase-4) inhibitors,
diagnosed as having angiosarcoma.
two (6.2%)used glucagon-like peptide-1 (GLP-1) agonists,
three (9%) used basal insulin, four (12.5%) used intensive
3.5. Glucose metabolism
insulin, one (3%) used sulfonylurea, and one (3%) patient
At the last follow-up, a mean increase of 11.3 mg/dL in
was using a sodium‐glucose cotransporter 2 (SGLT2)
FBG and 1% in HbA1c levels was observed. Although
inhibitor.
there was a significant increment between the pretreatment
and 3rd-month FBG (p = 0.008), no significant difference
4. Discussion
was found between pretreatment and 6th month and last
We observed significant improvements in the
follow-up FBG (p = 0.126 and p = 0.070, respectively).
hypercortisolemia levels of the patients. No serious adverse
There was a significant increment between pretreatment
effects were observed, except for glucose dysregulation.
HbA1c values and the 3rd-month (5.8 [5.4–6.3] vs. 6.4
Although dysregulation in glucose was observed at the
[5.9–7.0], p = 0.007), 6th-month (5.8 [5.4–6.3] vs. 6.6
3rd month of pasireotide treatment, the target HbA1c was
[6.2–7.5] p = 0.003), and last follow-up HbA1c values
achieved in most patients. There was a significant decrease
(5.8 [5.4–6.3] vs. 5.9 [6.3–8.4], p = 0.001). No significant
in the weight of the patients.
correlation was found between the 3rd-month UFC (93.
The normalization rates of UFC with pasireotide
[51.3–220.5]) and 3rd-month FBG (101.0 [88.5–122.5]), (r
treatment in CD range from 34.5% to 68.8%
= 0.023, p = 0.935), but there was a positive correlation
[27,28,29,30,31]. Previous studies confirmed that the rate
between the 3rd-month UFC (93. [51.3–220.5]) and
of UFC normalization rate increased as the duration of
3rd-month HbA1c (6.4 [6.0–7.1]) (r = 0.513, p = 0.029).
pasireotide treatment was prolonged [29,30]. Another
The associations between UFC–FBG and UFC–HbA1c
parameter affecting the UFC normalization rate is disease
during pasireotide treatment are shown in Figure 2 and
severity. Normalization rates were higher in patients
3. Prepasireotide treatment, 11 (34.3%) patients had a
with mild and moderate UFC values before pasireotide
diagnosis of T2DM, and seven (21.8%) patients had a
[27,30]. From this point of view, in our study, the UFC
prediabetes diagnosis. Prepasireotide treatment, 10 (31.2
normalization rate was lower compared with previous
%) patients were using metformin, two (6.2 %) used DPPstudies. However, some points should be taken into
4 (dipeptidyl peptidase-4) inhibitors, three (9.3 %) used
consideration while evaluating these results. The rate of
basal insulin, one (3.1 %) used sulfonylurea. In the third
month of treatment, T2DM developed in four (12.5%)
severe disease was high, and we did not include patients
patients with prediabetes, and prediabetes developed
who received radiotherapy in this group, even if their
in four (12.5%) patients. In 21 of 27 (77%) patients who
UFC values returned to normal, regardless of the time of
Figure 2 The association of UFC and FBG during pasireotide treatment
200.00

120.00

FBG

UFC

115.00

110.00
105.00

100.00

100.00
95.00

50.00

Initial

3rd month

6 th month

12th month

24th month

UFC: Urinary free cortisol, FBG: Fasting blood glucose
Figure 2. The association of UFC and FBG during pasireotide treatment.
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Figure 3 The associaton of UFC and HbA1c during pasireotide treatment
200.00

7.50

UFC

HbA1c
7.00

6.50

HbA1c, %

UFC, mg/gün

150.00

100.00
6.00
Initial

3rd month

6th month

12th month

24th month

50.00

5.50

UFC: Urinary free cortisol
Figure 3. The associaton of UFC and HbA1c during pasireotide treatment.

radiotherapy. In addition, in line with previous studies,
our patients with mild to moderate hypercortisolemia
responded better and faster to treatment. Pretreatment
UFC values can guide in terms of patient selection. It may
be more rational to consider pasireotide treatment mostly
in patients with mild and moderate UFC values.
The prevalence of hypertension in CD is 55%–85% [32]
and contributes to cardiovascular risk [33]. In a study by
Pivonello et al., similar decreases in systolic and diastolic
blood pressures were found postpasireotide treatment in
controlled and uncontrolled patients [34]. Accordingly,
the authors reported that pasireotide treatment improved
hypertension independent of a cortisol reduction [34]. In
this respect, similar results can be seen when looking at our
results. Significant decreases were detected postpasireotide
treatment in our patients, and there was no significant
difference between the controlled and uncontrolled
patients in terms of systolic and diastolic blood pressures.
In addition, the blood pressures of all patients (controlled
and uncontrolled patients) were found to be within the
normal range at the last follow-ups. Thus, pasireotide
treatment may improve hypertension independent of
decreases in cortisol. However, studies involving larger
numbers of patients are needed to clarify this issue.
Hyperglycemia is one of the important points to be
considered, especially in the management of pasireotide
treatment. It is seen that patients receiving pasireotide
treatment need more antidiabetic drugs during the
treatment process [27,30]. We also found similar results.
However, in the majority of patients receiving pasireotide
treatment, glucose dysregulation was under control in the
early period. Similar to previous studies, hyperglycemia
was controlled in the early phase of pasireotide treatment

in our study [27–29,35,36]. In other words, although
hyperglycemia seems to be an important problem in
pasireotide treatment, it can be overcome with successful
antidiabetic treatment.
Previous studies have attempted to clarify the
mechanism of pasireotide-induced hyperglycemia. In a
study in healthy volunteers, it was shown that pasireotide
caused a decrease in incretin and insulin secretion, and did
not cause any changes in insulin sensitivity [37]. Clinical
studies also support this situation. Breitschaft et al. showed
that vildagliptin and liraglutide were more effective in
controlling pasireotide-induced hyperglycemia [38]. In
our study, 56% of the patients who received antidiabetic
treatment were using DPP4-inhibitors, and 6.2% used
GLP1 agonists. However, the duration of the study by
Breitschaft et al. was one week, and therefore, it was a short
time for observing the long-term effects of antidiabetic
agents in lowering pasireotide-induced hyperglycemia.
Longer and prospective studies may shed light on this
issue.
Our analysis showed that there was a positive
correlation between the 3rd-month UFC and 3rd-month
HbA1c. Although this result was not very strong, it
supports that hyperglycemia was not solely due to the
effect of pasireotide treatment, but also endogenous
hypercortisolism because this affects postprandial glucose
rather than FBG [39]. However, glycemic control was
found independent of UFC responses in previous studies
[27,30]. The hyperglycemia mechanism of pasireotide
treatment was only performed on healthy volunteers [37];
therefore, the development mechanisms in the patient
population are not fully known. For this reason, more
studies are needed on this issue.
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Gastrointestinal disorders associated with the
pasireotide treatment are generally tolerable and
temporary. In the first 12 months of the phase III study
conducted by Colao et al., nine (6.6%) patients had bile
sludge, 27 (19.7%) patients had gallstones, and six (3.7%)
patients underwent cholecystectomy. Transient slight
increases in liver enzymes were found in 29% of patients
[27]. In another study, it was observed that the symptoms
of patients with nausea (21.4%) and vomiting (14.3%)
regressed spontaneously within a few weeks or months,
only one patient was unresponsive to medical treatment,
and two (14.3%) patients had diarrhea that improved with
loperamide [36]. Similar results to previous studies were
found in our study. Accordingly, although gastrointestinal
symptoms do not cause serious problems during
pasireotide treatment, they have an important place in
treatment follow-up. In very few cases, discontinuation of
pasireotide treatment or additional intervention may be
required.
Our study has a few limitations. First, our sample size
is small due to the rarity of the disease and the scarcity
of cases suitable for treatment. Secondly, the data of
some patients are lacking due to the retrospective design.
Thirdly, the effect of pasireotide on adenoma could not be
evaluated due to the lack of data.

In conclusion, pasireotide treatment is an alternative
to other treatments in patients with CD. Patients who
have controlled disease in the first months of treatment
continue this situation for an extended period. Although
glucose metabolism disorder is the most common adverse
effect, it can be successfully controlled. Further and
extensive studies are required to investigate factors that
predict the success or failure of the treatment and to better
understand the adverse effect mechanisms.
Funding
This research did not receive any specific grant from
funding agencies in the public, commercial, or not-forprofit sectors.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest
with respect to the research, authorship, and/or publication
of this article.
Acknowledgment
We would like to thank Professor Necmettin Tanrıöver,
Professor Nil Çomunoğlu, Professor Osman Kızılkılıç for
their contributions to the multidisciplinary treatment of
Cushing’s patients.

References
1. Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J
et al. Treatment of cushing’s syndrome: An endocrine society
clinical practice guideline. Journal of Clinical Endocrinology and
Metabolism 2015; 100(8):2807-2831. doi:10.1210/jc.2015-1818
2. Lindholm J, Juul S, Jørgensen JOL, Astrup J, Bjerre P et al. Incidence
and late prognosis of Cushing’s syndrome: A population-based
study. Journal of Clinical Endocrinology and Metabolism 2001;
86(1):117-123. doi:10.1210/jc.86.1.117
3. Arnardóttir S, Sigurjonsdóttir HA. The incidence and prevalence
of Cushing’s disease may be higher than previously thought:
Results from a retrospective study in Iceland 1955 through 2009.
Clinical Endocrinology 2011; 74(6):792-793. doi:10.1111/j.13652265.2010.03961.x
4. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ et al.
Mortality and morbidity in Cushing’s syndrome in New Zealand.
Clinical Endocrinology 2011; 75(4):436-442. doi:10.1111/j.1365
2265.2011.04124.x
5. Newell-Price J, Trainer P, Besser M, Grossman A. The Diagnosis
and Differential Diagnosis of Cushing’s Syndrome and PseudoCushing’s States. Endocrine Reviews 1998; 19(5):647-672.
doi:10.1210/edrv.19.5.0346
6. Giraldi FP, Moro M, Cavagnini F. Gender-related differences in
the presentation and course of Cushing’s disease. Journal of
Clinical Endocrinology and Metabolism 2003; 88(4):1554-1558.
doi:10.1210/jc.2002-021518

474

7. Lonser RR, Nieman L, Oldfield EH. Cushing’s disease: Pathobiology,
diagnosis, and management. Journal of Neurosurgery 2017;
126(2):404-417. doi:10.3171/2016.1.JNS152119
8. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality
and morbidity in Cushing’s disease over 50 Years in Stoke-onTrent, UK: Audit and meta-analysis of literature. Journal of
Clinical Endocrinology and Metabolism 2011; 96(3):632-642.
doi:10.1210/jc.2010-1942
9. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing’s disease:
An epidemiological approach. Clinical Endocrinology 1994;
40(4):479-484. doi:10.1111/j.1365-2265.1994.tb02486.x
10. Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen
JOL. Mortality in Cushing’s syndrome: A systematic review and
meta-analysis. European Journal of Internal Medicine 2012;
23(3):278-282. doi:10.1016/j.ejim.2011.10.013
11. Van Haalen FM, Broersen LHA, Jorgensen JO, Pereira AM, Dekkers
OM. Management of endocrine disease: Mortality remains
increased in Cushing’s disease despite biochemical remission:
A systematic review and meta-analysis. European Journal of
Endocrinology 2015; 172(4): R143-149. doi:10.1530/EJE-14-0556
12. Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK
et al. Mortality in patients with Cushing’s disease more than 10
years after remission: A multicentre, multinational, retrospective
cohort study. The Lancet Diabetes and Endocrinology 2016;
4(7):569-576. doi:10.1016/S2213-8587(16)30005-5

ŞAHİN et al. / Turk J Med Sci
13. Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan
ET et al. Transsphenoidal microsurgery for Cushing’s disease:
Initial outcome and long-term results. Journal of Clinical
Endocrinology and Metabolism 2004; 89(12):6348-6357.
doi:10.1210/jc.2003-032180
14. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan
B. Long-term remission rates after pituitary surgery for
Cushing’s disease: The need for long-term surveillance.
Clinical Endocrinology 2005; 63(5):549-559. doi:10.1111/
j.1365-2265.2005.02380.x
15. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO et al.
Late recurrences of Cushing’s disease after initial successful
transsphenoidal surgery. Journal of Clinical Endocrinology
and Metabolism 2008; 93(2):358-362. doi:10.1210/jc.20072013

25. Cuevas-Ramos D, Fleseriu M. Treatment of Cushing’s disease:
a mechanistic update. J Endocrinol 2014; 223(2): R19-39.
doi:10.1530/JOE-14-0300
26. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH
et al. Clinical Practice Guidelines for the Management
of Hypertension in the Community: A Statement by the
American Society of Hypertension and the International
Society of Hypertension Clinical Practice Guidelines for
the Management of Hypertension in the Comm. Journal of
Clinical Hypertension 2014; 32(1):3-15. doi:10.1111/jch.12237
27. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F et al. A
12-Month Phase 3 Study of Pasireotide in Cushing’s Disease.
New England Journal of Medicine 2012; 8;366(10):914-924.
doi:10.1056/nejmoa1105743

16. Aranda G, Enseñat J, Mora M, Puig-Domingo M, Martínez de
Osaba MJ et al. Long-term remission and recurrence rate in a
cohort of Cushing’s disease: the need for long-term follow-up.
Pituitary 2015; 18(1):142-149. doi:10.1007/s11102-014-0567-8

28. Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L,
Arnaldi G et al. Long-term treatment of Cushing’s disease
with pasireotide: 5-year results from an open-label extension
study of a Phase III trial. Endocrine 2017; 57(1):156-165.
doi:10.1007/s12020-017-1316-3

17. Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X
et al. Treatment of adrenocorticotropin-dependent cushing’s
syndrome: A consensus statement. Journal of Clinical
Endocrinology and Metabolism 2008; 93(7):2454-2462.
doi:10.1210/jc.2007-2734

29. Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J et al.
Pasireotide can induce sustained decreases in urinary cortisol
and provide clinical benefit in patients with Cushing’s disease:
results from an open-ended, open-label extension trial.
Pituitary 2015; 18(5):604-612. doi:10.1007/s11102-014-0618-1

18. Ambrogio AG, Cavagnini F. Role of “old” pharmacological
agents in the treatment of Cushing’s syndrome. Journal
of Endocrinological Investigation 2016; 39(9):957-965.
doi:10.1007/s40618-016-0462-4

30. Trementino L, Michetti G, Angeletti A, Marcelli G, Concettoni
C et al. A Single-Center 10-Year Experience with Pasireotide
in Cushing’s Disease: Patients’ Characteristics and Outcome.
Hormone and Metabolic Research 2016; 48(5):290-298.
doi:10.1055/s-0042-101347

19. Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M,
Honegger J et al. Long-term remission and recurrence rates
after first and second transsphenoidal surgery for Cushing’s
disease: Care reality in the munich metropolitan region.
European Journal of Endocrinology 2014; 21;170(2):283-292.
doi:10.1530/EJE-13-0634
20. Gadelha MR, Neto LV. Efficacy of medical treatment in Cushing’s
disease: A systematic review. Clinical Endocrinology 2014;
80(1):1-12. doi:10.1111/cen.12345
21. Losa M, Picozzi P, Redaelli MG, Laurenzi A, Mortini P. Pituitary
radiotherapy for Cushing’s disease. Neuroendocrinology 2010;
92 Suppl 1:107-110. doi:10.1159/000314299
22. Van der Hoek J, Waaijers M, Van Koetsveld PM, Sprij-Mooij
D, Feelders RA et al. Distinct functional properties of native
somatostatin receptor subtype 5 compared with subtype 2
in the regulation of ACTH release by corticotroph tumor
cells. American Journal of Physiology-Endocrinology and
Metabolism 2005; 289(2): E278-287
23. Van der Hoek J, Lamberts SWJ, Hofland LJ. The role of
somatostatin analogs in Cushing’s disease. Pituitary 2004; 7(4):
257-264.doi: 10.1007/s11102-005-1404-x
24. Bruin C de, Feelders RA, Lamberts SWJ, Hofland LJ. Somatostatin
and dopamine receptors as targets for medical treatment of
Cushing’s syndrome. Rev Endocr Metab Disord 2008; 10(2):91102. doi:10.1007/s11154-008-9082-4

31. Fleseriu M, Iweha C, Salgado L, Mazzuco TL, Campigotto F et al.
Safety and efficacy of subcutaneous pasireotide in patients with
Cushing’s disease: Results from an open-label, multicenter,
single-arm, multinational, expanded-access study. Frontiers in
Endocrinology 2019; 16; 10:436. doi:10.3389/fendo.2019.00436
32. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of
Cushing’s disease: Clinical and health-related quality of life
aspects. European Journal of Endocrinology 2012; 167(3):311326. doi:10.1530/EJE-11-1095
33. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D et al.
Persistence of increased cardiovascular risk in patients with
cushing’s disease after five years of successful cure. Journal
of Clinical Endocrinology and Metabolism 1999; 84(8):26642672. doi:10.1210/jcem.84.8.5896
34. Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F et al.
Pasireotide treatment significantly improves clinical signs and
symptoms in patients with Cushing’s disease: Results from a
Phase III study. Clinical Endocrinology 2014; 81(3):408-417.
doi:10.1111/cen.12431
35. Simeoli C, Ferrigno R, De Martino MC, Iacuaniello D, Papa F
et al. The treatment with pasireotide in Cushing’s disease:
effect of long-term treatment on clinical picture and metabolic
profile and management of adverse events in the experience of
a single center. Journal of Endocrinological Investigation 2020;
43(1):57-73. doi:10.1007/s40618-019-01077-8

475

ŞAHİN et al. / Turk J Med Sci
36. Yedinak CG, Hopkins S, Williams J, Ibrahim A, Cetas JS et al.
Medical therapy with pasireotide in recurrent Cushing’s
disease: Experience of patients treated for at least 1 year at
a single center. Frontiers in Endocrinology 2017; 27; 8:35.
doi:10.3389/fendo.2017.00035

38. Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor
G. Management of hyperglycemia associated with pasireotide
(SOM230): Healthy volunteer study. Diabetes Research
and Clinical Practice 2014; 103(3):458-465. doi:10.1016/j.
diabres.2013.12.011

37. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan
M et al. Hyperglycemia associated with pasireotide: Results
from a mechanistic study in healthy volunteers. Journal of
Clinical Endocrinology and Metabolism 2013; 98(8):34463453. doi:10.1210/jc.2013-1771

39. Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro
M. Advances in the epidemiology, pathogenesis, and
management of Cushing’s syndrome complications. Journal
of Endocrinological Investigation 2012; 35(4):434-448.
doi:10.1007/BF03345431

476

